Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review

[1]  F. Piacentini,et al.  Carcinoid Crisis: A Misunderstood and Unrecognized Oncological Emergency , 2022, Cancers.

[2]  R. Salem,et al.  Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database , 2021, The Journal of Nuclear Medicine.

[3]  F. Collettini,et al.  Combining Transarterial Radioembolization (TARE) and CT-Guided High-Dose-Rate Interstitial Brachytherapy (CT-HDRBT): A Retrospective Analysis of Advanced Primary and Secondary Liver Tumor Treatment , 2021, Cancers.

[4]  R. de Bree,et al.  First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer , 2021, EJNMMI Research.

[5]  G. Brandi,et al.  Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials , 2021, Expert opinion on investigational drugs.

[6]  R. Salem,et al.  Radiation Lobectomy: An Overview of Concept and Applications, Technical Considerations, Outcomes , 2021, Seminars in Interventional Radiology.

[7]  G. Johnson,et al.  Recognizing and Managing Adverse Events in Y-90 Radioembolization , 2021, Seminars in Interventional Radiology.

[8]  I. Nabipour,et al.  Feasibility and Therapeutic Potential of 177Lu–Fibroblast Activation Protein Inhibitor–46 for Patients With Relapsed or Refractory Cancers , 2021, Clinical nuclear medicine.

[9]  R. Baum,et al.  Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results , 2021, The Journal of Nuclear Medicine.

[10]  K. Rahbar,et al.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. , 2021, The New England journal of medicine.

[11]  L. Portelance,et al.  Lung shunt fraction calculation using 99mTc-MAA SPECT/CT imaging for 90Y microsphere selective internal radiation therapy of liver tumors , 2021, EJNMMI Research.

[12]  E. Mittra,et al.  Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. , 2021 .

[13]  S. Kappadath,et al.  Reassessment of the lung dose limits for radioembolization , 2021, Nuclear medicine communications.

[14]  V. Bhargavi,et al.  Transarterial Radioembolization (TARE) with 131 Iodine-Lipiodol for Unresectable Primary Hepatocellular Carcinoma: Experience from a Tertiary Care Center in India , 2021, South Asian Journal of Cancer.

[15]  D. Fraker,et al.  The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma , 2021, Pancreas.

[16]  B. Mittal,et al.  Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis , 2021, Prostate Cancer and Prostatic Diseases.

[17]  Emily B. Ehlerding,et al.  CD38‐Targeted Theranostics of Lymphoma with 89Zr/177Lu‐Labeled Daratumumab , 2021, Advanced science.

[18]  D. Bailey,et al.  Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker , 2021, The Journal of Nuclear Medicine.

[19]  M. Stockler,et al.  [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial , 2021, The Lancet.

[20]  D. Bailey,et al.  Overlooked potential of positrons in cancer therapy , 2021, Scientific Reports.

[21]  Weibing Tang,et al.  Comparison of Incidence and Outcomes of Neuroblastoma in Children, Adolescents, and Adults in the United States: A Surveillance, Epidemiology, and End Results (SEER) Program Population Study , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[22]  H. G. van der Poel,et al.  Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial , 2020, BMC cancer.

[23]  D. Metz,et al.  The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors , 2020, Pancreas.

[24]  M. McDevitt,et al.  Radiopharmaceutical therapy in cancer: clinical advances and challenges , 2020, Nature Reviews Drug Discovery.

[25]  P. Rubio,et al.  MIBG Therapy for Neuroblastoma: Precision Achieved With Dosimetry, and Concern for False Responders , 2020, Frontiers in Medicine.

[26]  J. Fleming,et al.  Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy , 2020, The Journal of Nuclear Medicine.

[27]  V. Gebski,et al.  Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNET , 2020 .

[28]  I. B. Borel Rinkes,et al.  68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617 , 2020, EJNMMI Research.

[29]  S. Severi,et al.  Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  N. Douthit,et al.  Carcinoid Syndrome: A Review , 2020, Cureus.

[31]  Mengjiao Wang,et al.  The therapeutic efficacy of 177Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors , 2020, Medicine.

[32]  J. Berkes,et al.  Position 2: Transarterial Radioembolization Should Be the Primary Locoregional Therapy for Unresectable Hepatocellular Carcinoma , 2020, Clinical liver disease.

[33]  Michael M C Sun,et al.  Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer , 2020, Cureus.

[34]  Hussein M. K. Al-Masri,et al.  Indian management research , 1983, The Political Economy of Participatory Economics.

[35]  Peter Schirmacher,et al.  The 2019 WHO classification of tumours of the digestive system , 2019, Histopathology.

[36]  B. Mittal,et al.  177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis. , 2019, Nuclear medicine communications.

[37]  R. Reilly,et al.  Auger electrons for cancer therapy – a review , 2019, EJNMMI Radiopharmacy and Chemistry.

[38]  D. Fuhrer,et al.  2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer , 2019, European Thyroid Journal.

[39]  W. Oyen,et al.  EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  J. Nijsen,et al.  The various therapeutic applications of the medical isotope holmium-166: a narrative review , 2019, EJNMMI Radiopharmacy and Chemistry.

[41]  R. Knudsen.  Controversies , 2019, International Society of Hair Restoration Surgery.

[42]  D. Metz,et al.  NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE , 2019, The Journal of Nuclear Medicine.

[43]  F. Hindré,et al.  Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives , 2019, Front. Med..

[44]  A. Buck,et al.  Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). , 2019, Journal of Clinical Oncology.

[45]  Prashanth Rawla,et al.  Epidemiology of Prostate Cancer , 2019, World journal of oncology.

[46]  P. Bogner,et al.  Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC). , 2019, Journal of Clinical Oncology.

[47]  F. Bruchertseifer,et al.  225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[48]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers , 2018, The Journal of Nuclear Medicine.

[49]  J. Ramage,et al.  Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. , 2018, Seminars in oncology.

[50]  B. Dai,et al.  National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients , 2018, Asian journal of andrology.

[51]  G. Kaltsas,et al.  Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. , 2018, Annals of translational medicine.

[52]  P. Choyke,et al.  Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents , 2018, Translational andrology and urology.

[53]  N. Pavlakis,et al.  Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions. , 2018, Cancer treatment reviews.

[54]  U. Haberkorn,et al.  PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter? , 2018, The Journal of Nuclear Medicine.

[55]  H. Lundqvist,et al.  Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[56]  G. Kristiansen,et al.  Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role , 2018, The Journal of urology.

[57]  Wen-Jeng Wu,et al.  Optimal usage of radium-223 in metastatic castration-resistant prostate cancer. , 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

[58]  E. Krenning,et al.  Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine , 2017, The Journal of Nuclear Medicine.

[59]  J. Nijsen,et al.  Intratumoral treatment with radioactive beta-emitting microparticles: a systematic review , 2017, Journal of Radiation Oncology.

[60]  Rolf Fimmers,et al.  Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[61]  R. Bellavia,et al.  Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma. , 2017, Journal of gastrointestinal oncology.

[62]  G. Feldmann,et al.  The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[63]  Edward Hsiao,et al.  Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance , 2017, Theranostics.

[64]  J. Berlin,et al.  Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.

[65]  W. Brenner,et al.  German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients , 2017, Journal of Nuclear Medicine.

[66]  Kaliszewski,et al.  American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .

[67]  V. Kunam,et al.  Administered activity and outcomes of glass versus resin (90)Y microsphere radioembolization in patients with colorectal liver metastases. , 2016, Journal of gastrointestinal oncology.

[68]  J. Neuhaus,et al.  Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. , 2016, European journal of cancer.

[69]  U. Haberkorn,et al.  The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[70]  G. Fave,et al.  Controversies in the treatment of digestive neuroendocrine tumors , 2016 .

[71]  M. Chojnowski,et al.  Radionuclide synovectomy – essentials for rheumatologists , 2016, Reumatologia.

[72]  S. Basu,et al.  Favorable Response of Metastatic Merkel Cell Carcinoma to Targeted 177Lu-DOTATATE Therapy: Will PRRT Evolve to Become an Important Approach in Receptor-Positive Cases? , 2016, The Journal of Nuclear Medicine Technology.

[73]  P. Meyer,et al.  Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine–Labeled CD30-Specific AC-10 Antibody , 2016, The Journal of Nuclear Medicine.

[74]  A. Dash,et al.  Radionuclide Synovectomy: Treatment of Inflammation of the Synovial Joints , 2016 .

[75]  S. Groshen,et al.  131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[76]  U. Haberkorn,et al.  PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[77]  U. Haberkorn,et al.  [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[78]  T. Holland-Letz,et al.  The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[79]  A. Kennedy.  Radioembolization of hepatic tumors. , 2014, Journal of gastrointestinal oncology.

[80]  W. Oyen,et al.  Theranostic applications of antibodies in oncology , 2014, Molecular oncology.

[81]  A. A. Goodarzi,et al.  The repair of environmentally relevant DNA double strand breaks caused by high linear energy transfer irradiation--no simple task. , 2014, DNA repair.

[82]  B. Hadaschik,et al.  Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[83]  J. Becker,et al.  Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging , 2014, BMC Cancer.

[84]  A. Agrawal,et al.  90Y microsphere therapy: does 90Y PET/CT imaging obviate the need for 90Y Bremsstrahlung SPECT/CT imaging? , 2013, Nuclear medicine communications.

[85]  B. van Eck-Smit,et al.  Long‐term follow‐up of the thyroid gland after treatment with 131I‐Metaiodobenzylguanidine in children with neuroblastoma: Importance of continuous surveillance , 2013, Pediatric blood & cancer.

[86]  R. Herrmann,et al.  Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas , 2013, The Journal of Nuclear Medicine.

[87]  R. Hawkins,et al.  131I‐MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma , 2013, Pediatric blood & cancer.

[88]  F. Berthold,et al.  Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  H. Kang,et al.  Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma , 2013, Cancer Chemotherapy and Pharmacology.

[90]  M. Kaminski,et al.  Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  B. Sangro,et al.  Dosimetry and Dose Calculation , 2013 .

[92]  J. Martí-Climent,et al.  Nuclear Medicine Procedures for Treatment Evaluation and Administration , 2013 .

[93]  R. Herrmann,et al.  Radioimmunotherapy with 177 Lu-DOTA-Rituximab : Final Results of a Phase I / II Study in 31 Patients with Relapsing Follicular , Mantle Cell , and Other Indolent B-Cell Lymphomas , 2013 .

[94]  D. Hörsch,et al.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[95]  P. Albertsson,et al.  Intraperitoneal Radionuclide Therapy – Clinical and Pre-Clinical Considerations , 2012 .

[96]  S. Vallabhajosula,et al.  Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology. , 2011, Seminars in nuclear medicine.

[97]  F. Izzo,et al.  Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases , 2010, British Journal of Cancer.

[98]  Lewington,et al.  Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force , 2010, British Journal of Cancer.

[99]  B. Wessels,et al.  MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy* , 2010, Journal of Nuclear Medicine.

[100]  R. Valkema,et al.  Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[101]  G. Klöppel,et al.  Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. , 2009, World journal of gastroenterology.

[102]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[103]  E. Thiel,et al.  First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. , 2009, Neuro-oncology.

[104]  A. Benson,et al.  Radioembolization of colorectal hepatic metastases using yttrium‐90 microspheres , 2009, Cancer.

[105]  T. Illidge,et al.  Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. , 2009, Blood.

[106]  W. Oyen,et al.  Guidelines for radioiodine therapy of differentiated thyroid cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[107]  H. Caron,et al.  Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. , 2008, European journal of cancer.

[108]  A. Chiti,et al.  EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[109]  S. Swerdlow,et al.  Radioisotopic Localization of 90Yttrium–Ibritumomab Tiuxetan in Patients with CD20+ Non-Hodgkin’s Lymphoma , 2008, Molecular Imaging and Biology.

[110]  Su-Chun Cheng,et al.  Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  R. Hicks,et al.  Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  T. Visser,et al.  Localisation and mechanism of renal retention of radiolabelled somatostatin analogues , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[113]  S. Adelstein,et al.  Radiobiologic principles in radionuclide therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[114]  C. Hoefnagel.  Radionuclide therapy revisited , 2005, European Journal of Nuclear Medicine.

[115]  H. Gerstein,et al.  A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer , 2004 .

[116]  Sam S. Chang.  Overview of prostate-specific membrane antigen. , 2004, Reviews in urology.

[117]  L. Gordon,et al.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  Otto C. Boerman,et al.  Radioimmunotherapy of B-cell non-Hodgkin's lymphoma , 2001, European Journal of Nuclear Medicine.

[120]  J. Erion,et al.  Therapy studies with [Lu-177]-DOTA-Y3-Octreotate in CA20948 tumor-implanted Lewis rats , 2000 .

[121]  C. Herold,et al.  Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[122]  T. Visser,et al.  Pre‐clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor‐targeted scintigraphy and radionuclide therapy , 1998, International journal of cancer.

[123]  B. Hasegawa,et al.  Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  J. Zweit,et al.  Radionuclides and carrier molecules for therapy. , 1996, Physics in medicine and biology.

[125]  J. Lumbroso,et al.  Metastatic neuroblastoma in children older than one year: Prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system , 1996, Cancer.

[126]  J C Reubi,et al.  Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[127]  A. Peters,et al.  Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. , 1993, British Journal of Cancer.

[128]  P. Reuland,et al.  Treatment of neuroblastoma with [131I]metaiodobenzylguanidine: long-term results in 25 patients. , 1991, Journal of nuclear biology and medicine.

[129]  W A Volkert,et al.  Therapeutic radionuclides: production and decay property considerations. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[130]  J. Reubi,et al.  Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. , 1987, The Journal of clinical endocrinology and metabolism.

[131]  D. E. Troutner.  Chemical and physical properties of radionuclides. , 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[132]  A European association of nuclear medicine. , 1984, Nuclear medicine communications.